胸腺肽α_1及乌司他丁对严重脓毒症患者免疫功能的影响  

Effects of thymosin-α_1 combined ulinastatin on immunity in patients with severe sepsis

作　　者：邓梦华[1] 潘永[1] 张斌[1] 林旋[1] 徐杰[1] 

机构地区：[1]佛山市中医院,广东佛山528000

出　　处：《山东医药》2007年第7期19-20,共2页Shandong Medical Journal

基　　金：北京市科技计划重大项目(全国临床多中心课题)(2002-641)

摘　　要：目的评价胸腺肽α1联合乌司他丁对脓毒症患者免疫功能的影响。方法将32例患者随机分成治疗组和对照组,对照组采用常规治疗,治疗组在常规治疗基础上加胸腺肽α1和乌司他丁,观察两组患者治疗后APACHEⅡ评分、MarsheⅡ评分、CD14+单核细胞HLA-DR水平变化。结果与对照组比较,治疗组CD14+单核细胞HLA-DR水平明显升高(P<0.05),APACHEⅡ、MarsheⅡ评分平显著下降(P<0.05),入住ICU天数明显缩短(P<0.05)。结论胸腺肽α1联合乌司他丁治疗脓毒症可提高患者的免疫力,抑制过度炎症反应。[Objective] To investigate the effects of thymosin-α1 combine ulinastatin on immunity in patients with severe sepsis. [Methods] 32 patients were divided into two groups randomly： therapy group and control group. The control group was given routine therapy while the therapy group was given routine therapy and thymosin-α1, ulinastatin for seven days, and the scores of APACHE Ⅱ and Marshell, the number of lymphocyte arid the ICU length of stay were recorded. [Results] After treatment, compared with the control group, levels of HLA-DR in therapy group increased significantly （P〈0.05） while the scores of APACHE Ⅱ .Marshell were decreased slgnificangtly （P〈0.05）, the ICU length of stay decreased significantly also. [Conclusion] Thymosin-α1 combined ulinastatin can help to improve the immunity of severe patients, attenuate the system inflammatory response of sepsis and decrease the ICU length of stay.

关 键 词：脓毒症 胸腺肽Α1 乌司他丁 CD14+单核细胞HLA-DR 

分 类 号：R631.2[医药卫生—外科学]